November 2, 2020Open Access
Aspirin for primary prevention of cardiovascular events in people with diabetes: A position statement of the american diabetes association, a scientific statement of the american heart association, and an expert consensus document of the american college of cardiology foundation
Why the study?
Patients with diabetes have a substantially increased risk of cardiovascular events, but the net benefit of aspirin for primary prevention in individuals with no previous cardiovascular events remains controversial.
Does aspirin reduce cardiovascular morbidity and mortality in patients with diabetes for primary prevention?
Population
People with diabetes
Comparison
Aspirin vs no aspirin
Design
Position statement, scientific statement, and expert consensus document
Authors
Discussion
Loading...
Member takes
Implication
Should inform aspirin use for primary prevention in high-risk diabetes; reinforces ADA/AHA/ACCF consensus.
Key Points
- This position statement evaluates the role of aspirin in preventing cardiovascular events in individuals with diabetes.
- Reviewed cardiovascular risk factors and mechanisms specific to diabetic patients.
- Analyzed recent guidelines and recommendations from reputable health organizations.
- Discussed aspirin's role in primary prevention among different age groups and risk profiles.
- FDA has not approved aspirin for primary prevention in individuals without previous cardiovascular events.
- U.S. Preventive Services Task Force recommends aspirin for men 45-79 and women 55-79 years old.
- ADA and AHA reaffirmed aspirin use in diabetes patients over 40 or with additional risk factors.
Structured PICO
Does aspirin reduce cardiovascular morbidity and mortality in patients with diabetes for primary prevention?
P
Population
Patients with diabetes with no previous cardiovascular events (primary prevention)
I
Intervention
Aspirin therapy (75-162 mg/day)
O
Outcome
Cardiovascular morbidity and mortalityhard clinical
This document provides expert consensus and position statements from the ADA, AHA, and ACCF regarding the use of aspirin for the primary prevention of cardiovascular events in patients with diabetes.
Cite This Study
Wilson et al. (2020) conducted a review in Diabetes and cardiovascular disease. Aspirin was evaluated. Aspirin therapy (75-162 mg/day) is recommended as a primary prevention strategy for cardiovascular events in patients with diabetes at increased cardiovascular risk.